Perilymph is considered the sole source of nutritional supply to the cochlear hair cells as well as the sole carrier for the elimination of metabolites. An increase of the perilymph turnover rate implies an improvement of the hair cell metabolism. Any drug that enhances perilymph production might be a useful agent for the treatment of acute inner ear lesions like sudden deafness, acoustic trauma and lesions following ear surgery. The influence of various pharmacological agents on the perilymph production rate is studied and their possible use for the treatment of inner ear affections is discussed. Vasodilating drugs failed to achieve significant production rises; favourable results were obtained with ergot alkaloides; most effective were plasma volume expanders and respiratory acidosis. In accordance with the assumption of different production modes (active secretion of cerebrospinal fluid; ultrafiltration of perilymph), perilymph production does not parallel with the cerebrospinal fluid in its pharmacological behaviour.

Keywords:
Perilymph, Inner ear lesions
This content is only available via PDF.
© 1974 S. Karger AG, Basel
1974
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.